BioSpace News Archive

Forecast to 2027,’ thoroughly examines the Multiparameter Patient Monitoring industry to provide essential data & information for the targeted readers.

A recent report provides crucial insights along with application based and forecast information in the Global Procalcitonin Market.

The global Spinal Trauma Devices market size is estimated to be worth US$ 12740 million in 2021 and is forecast to a readjusted size of US$ 17880 million by 2030 with a CAGR of 4.9% during the forecast period 2022-2030.

The global Varicella Vaccine market size is estimated to be worth US$ 4174 million in 2021 and is forecast to a readjusted size of US$ 7104.7 million by 2030 with a CAGR of 7.8% during the forecast period 2022-2030.

Tampa General Hospital and USF Health Morsani College of Medicine physicians are the first in Hillsborough County to bring patients experiencing recurring brain tumors a groundbreaking treatment.

Median Technologies (ALMDT) (Paris:ALMDT) announced today that the Company will be participating in the 2022 European Congress of Radiology (ECR), to be held in Vienna, Austria, July 13-17.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 3, 2022.

Mersana Therapeutics, Inc. announced that on July 1, 2022, an authorized sub-committee of the Compensation Committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 25,575 shares of its common stock and restricted stock unit awards to acquire an aggregate of 47,925 shares of its common stock, to 8 new employees whose employment commenced in June 2022.

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that the results of the pivotal Phase II of its Investigational Device Exemption (“IDE”) study evaluating the safety and effectiveness of the Renuvion device to improve the appearance of lax skin in the neck and submental region have been posted on ClinicalTrials.gov.

MacroGenics, Inc. (NASDAQ: MGNX), today announced that effective as of July 7, 2022, the Company closed the Phase 2 study (CP-MGA271-06) evaluating the investigational regimen of enoblituzumab (Fc-optimized B7-H3-directed monoclonal antibody) in combination with either retifanlimab (anti-PD-1 monoclonal antibody) or tebotelimab (PD-1 × LAG-3 bispecific DART® molecule) in the first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).